A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma

Background Hepatocellular carcinoma (HCC) cells are auxotrophic for arginine, depletion of which leads to tumour regression. The current study evaluated safety, pharmacokinetics (PK)/ pharmacodynamics (PD) parameters, and potential anti-tumor activity of pegylated recombinant human arginase 1 (peg-r...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yau, Thomas, Cheng, P. N., Chan, Pierre, Chan, William, Chen, Li, Yuen, Jimmy, Pang, Roberta, Fan, S. T., Poon, Ronnie T.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2012
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3553413/
https://ncbi.nlm.nih.gov/pubmed/22426640
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9807-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados